JP2016527891A5 - - Google Patents

Download PDF

Info

Publication number
JP2016527891A5
JP2016527891A5 JP2016532782A JP2016532782A JP2016527891A5 JP 2016527891 A5 JP2016527891 A5 JP 2016527891A5 JP 2016532782 A JP2016532782 A JP 2016532782A JP 2016532782 A JP2016532782 A JP 2016532782A JP 2016527891 A5 JP2016527891 A5 JP 2016527891A5
Authority
JP
Japan
Prior art keywords
protein
peptide
mutant
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016532782A
Other languages
English (en)
Japanese (ja)
Other versions
JP6554099B2 (ja
JP2016527891A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2014/063777 external-priority patent/WO2015019318A1/en
Publication of JP2016527891A publication Critical patent/JP2016527891A/ja
Publication of JP2016527891A5 publication Critical patent/JP2016527891A5/ja
Application granted granted Critical
Publication of JP6554099B2 publication Critical patent/JP6554099B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016532782A 2013-08-07 2014-08-07 ｐ５３変異体を再活性化することの可能なペプチド Expired - Fee Related JP6554099B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862977P 2013-08-07 2013-08-07
US61/862,977 2013-08-07
PCT/IB2014/063777 WO2015019318A1 (en) 2013-08-07 2014-08-07 Peptides capable of reactivating p53 mutants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019125644A Division JP2019214573A (ja) 2013-08-07 2019-07-04 ｐ５３変異体を再活性化することの可能なペプチド

Publications (3)

Publication Number Publication Date
JP2016527891A JP2016527891A (ja) 2016-09-15
JP2016527891A5 true JP2016527891A5 (enExample) 2017-09-14
JP6554099B2 JP6554099B2 (ja) 2019-07-31

Family

ID=52460737

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016532782A Expired - Fee Related JP6554099B2 (ja) 2013-08-07 2014-08-07 ｐ５３変異体を再活性化することの可能なペプチド
JP2019125644A Pending JP2019214573A (ja) 2013-08-07 2019-07-04 ｐ５３変異体を再活性化することの可能なペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019125644A Pending JP2019214573A (ja) 2013-08-07 2019-07-04 ｐ５３変異体を再活性化することの可能なペプチド

Country Status (12)

Country Link
US (4) US9856289B2 (enExample)
EP (1) EP3030571B1 (enExample)
JP (2) JP6554099B2 (enExample)
CN (1) CN105579464B (enExample)
AU (2) AU2016200713B2 (enExample)
BR (1) BR112016002721A2 (enExample)
CA (1) CA2920147C (enExample)
ES (1) ES2795982T3 (enExample)
HU (1) HUE049292T2 (enExample)
IL (2) IL243944B (enExample)
RU (2) RU2693487C2 (enExample)
WO (1) WO2015019318A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105579464B (zh) 2013-08-07 2021-01-26 耶达研究及发展有限公司 能够再活化p53突变体的肽
CN105112377B (zh) * 2015-09-25 2018-10-30 福州迈新生物技术开发有限公司 一株分泌抗p53单克隆抗体的杂交瘤细胞株及其应用
CN108884137B (zh) * 2016-02-04 2022-04-05 耶达研究及发展有限公司 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途
US20220251159A1 (en) * 2016-02-04 2022-08-11 Yeda Research And Development Co., Ltd Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
FI3688027T3 (fi) * 2017-09-29 2025-12-09 Us Health Mutatoidun p53:n tunnistavia t-solureseptoreita
MA51056A (fr) 2017-12-07 2020-10-14 Reven Ip Holdco Llc Compositions et méthodes pour le traitement d'affections métaboliques
WO2019116376A1 (en) * 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
WO2019134650A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Mp53 rescue compounds and methods of treating a p53 disorder
US20200390743A1 (en) * 2019-06-12 2020-12-17 Reven Ip Holdco Llc Methods and Compositions For Improving Outcomes of Cancer Patients
JP7402026B2 (ja) 2019-11-27 2023-12-20 株式会社小松製作所 作業機械の制御システム、作業機械、作業機械の制御方法
WO2021186431A1 (en) 2020-03-16 2021-09-23 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with a mutant p53 protein
CN111574591B (zh) * 2020-04-29 2021-09-21 西安交通大学医学院第一附属医院 一种多肽及其合成方法
CN111686127B (zh) * 2020-06-04 2022-02-15 华南理工大学 锌铁纳米材料在降解突变p53蛋白中的应用
CN113750246B (zh) * 2020-06-04 2023-12-05 华南理工大学 ZIF-8纳米材料在降解广谱突变p53蛋白中的应用
US20230049952A1 (en) * 2020-06-24 2023-02-16 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function
CN112921032A (zh) * 2020-12-29 2021-06-08 苏州中科先进技术研究院有限公司 一种引物对、探针、试剂盒及其使用方法
CN115466786A (zh) * 2021-06-11 2022-12-13 上海交通大学医学院附属瑞金医院 一种筛选适合用p53复活药物治疗p53异常相关疾病病人的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294605A (en) 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5614393A (en) 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US5969120A (en) * 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US6169073B1 (en) * 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
WO1998051707A1 (fr) * 1997-05-15 1998-11-19 Kyowa Hakko Kogyo Co., Ltd. Peptides a structures cycliques et a effet restaurateur d'activite de la proteine p53 sur les mutants de ladite proteine
US20030224379A1 (en) * 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
ES2372686T3 (es) 2001-01-26 2012-01-25 Inhibitex, Inc. Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones.
US20040214184A1 (en) * 2001-02-28 2004-10-28 Skubitz Keith M Small peptides capable of modulating the function of cd66 (ceacam) family members
WO2003072600A2 (en) * 2002-01-23 2003-09-04 Gardner, Rebecca, Katherine Methods of screening molecular libraries for active molecules that restore the function of target proteins and peptides that restore the function of mutant p53
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
CA2600370A1 (en) * 2005-03-14 2006-09-14 Board Of Regents Of The University Of Texas System Bioactive fus1 peptides and nanoparticle-polypeptide complexes
US8877201B2 (en) * 2007-10-25 2014-11-04 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
EP2268658B1 (en) * 2008-03-13 2015-12-09 Universita'Degli Studi di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
SG11201401043SA (en) * 2011-09-09 2014-08-28 Agency Science Tech & Res P53 activating peptides
EP2771349B1 (en) * 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2014041505A1 (en) * 2012-09-13 2014-03-20 Universite De Geneve Cell penetrating peptides
CN105579464B (zh) 2013-08-07 2021-01-26 耶达研究及发展有限公司 能够再活化p53突变体的肽
CN108884137B (zh) 2016-02-04 2022-04-05 耶达研究及发展有限公司 肽及其在治疗与突变型p53相关的疾病、病症或病况中的用途

Similar Documents

Publication Publication Date Title
JP2016527891A5 (enExample)
RU2019119609A (ru) Пептиды, способные реактивировать мутанты р53
JP2017538401A5 (enExample)
JP2013172734A5 (enExample)
JP2011155981A5 (enExample)
JP2017018125A5 (enExample)
JP2017048194A5 (enExample)
JP2015525217A5 (enExample)
JP2009268467A5 (enExample)
JP2011136997A5 (enExample)
JP2017514522A5 (enExample)
JP2012095652A5 (enExample)
JP2016129515A5 (enExample)
JP2017212998A5 (enExample)
JP2010065037A5 (enExample)
JP2015525065A5 (enExample)
JP2015212284A5 (enExample)
JP2013530689A5 (enExample)
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
JP2013541335A5 (enExample)
JP2010512160A5 (enExample)
JP2015533791A5 (enExample)
JP2017501211A5 (enExample)
JP2010088434A5 (enExample)
IL269187B1 (en) Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal